TCR 工程化的 iNKT 细胞通过双重靶向癌症和抑制性髓系细胞诱导强大的抗肿瘤反应
TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells.
采用肿瘤特异性T细胞受体(TCR)工程化T细胞的过继性免疫疗法在癌症治疗中具有前景。
62.5分
★★★☆☆
FRONTIER PAPERS
TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells.
采用肿瘤特异性T细胞受体(TCR)工程化T细胞的过继性免疫疗法在癌症治疗中具有前景。
共 1 条
MEMBER ACCOUNT
登录成功会直接打开下一页。